Effects of calpain inhibition on dopaminergic markers and motor function following intrastriatal 6-hydroxydopamine administration in rats

Neuroscience

Volumn 158, Issue 2, 2009, Pages 558-569

  Grant, R J ^a   Sellings, L H L ^a   Crocker, S J ^b   Melloni, E ^c   Park, D S ^d   Clarke, P B S ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c UNIVERSITY OF GENOA   (Italy)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

6 hydroxydopamine; calpastatin; caspase; dopamine; motor; striatum

Indexed keywords

CALPAIN; CALPASTATIN; DOPAMINE TRANSPORTER; OXIDOPAMINE; SPECTRIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; ENZYME INHIBITION; MALE; MOTOR PERFORMANCE; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; RAT;

ADRENERGIC AGENTS; ANIMALS; AUTORADIOGRAPHY; CALCIUM-BINDING PROTEINS; CALPAIN; CASPASE 3; COCAINE; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FUNCTIONAL LATERALITY; GREEN FLUORESCENT PROTEINS; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; SPECTRIN; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 58149475992     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.10.023     Document Type: Article

References (93)

1. Altar C.A., Marien M.R., and Marshall J.F. Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioural recovery from brain injury. J Neurochem 48 (1987) 390-399
2. Andersen J.K. Does neuronal loss in Parkinson's disease involve programmed cell death?. Bioessays 23 (2001) 640-646
3. Andrew R., Watson D.G., Best S.A., Midgley J.M., Wenlong H., and Petty R.K. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res 18 (1993) 1175-1177
4. Ayala-Grosso C., Tam J., Xanthoudakis S., Bureau Y., Roy S., Nicholson D.W., and Robertson G.S. Effects of fimbria-fornix transection on calpain and choline acetyl transferase activities in the septohippocampal pathway. Neuroscience 126 (2004) 927-940
5. Barnéoud P., Parmentier S., Mazadier M., Miquet J.M., Boireau A., Dubédat P., and Blanchard J.-C. Effects of complete and partial lesions of the dopaminergic mesotelencephalic system on skilled forelimb use in the rat. Neuroscience 67 (1995) 837-848
6. Bezard E., Gross C.E., and Brotchie J.M. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 26 (2003) 215-221
7. Bi X., Chang V., Siman R., Tocco G., and Baudry M. Regional distribution and time-course of calpain activation following kainate-induced seizure activity in adult rat brain. Brain Res 726 (1996) 98-108
8. Bilang-Bleuel A., Revah F., Colin P., Locquet I., Robert J.J., Mallet J., and Horellou P. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioural impairment in a rat model of Parkinson disease. Proc Natl Acad Sci U S A 94 (1997) 8818-8823
9. Bizat N., Hermel J.M., Humbert S., Jacquard C., Creminon C., Escartin C., Saudou F., Krajewski S., Hantraye P., and Brouillet E. In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3. J Biol Chem 278 (2003) 43245-43253
10. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., and Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65 (2001) 135-172
11. Bowenkamp K.E., David D., Lapchak P.L., Henry M.A., Granholm A.C., Hoffer B.J., and Mahalik T.J. 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Exp Brain Res 111 (1996) 1-7
12. Cenci M.A., Whishaw I.Q., and Schallert T. Animal models of neurological deficits: how relevant is the rat?. Nat Rev Neurosci 3 (2002) 574-579
13. Cerruti C., Drian M.J., Kamenka J.M., and Privat A. Localization of dopamine carriers by BTCP, a dopamine uptake inhibitor, on nigral cells cultured in vitro. Brain Res 555 (1991) 51-57
14. Chang J.W., Wachtel S.R., Young D., and Kang U.J. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88 (1999) 617-628
15. Choi-Lundberg D.L., Lin Q., Schallert T., Crippens D., Davidson B.L., Chang Y.N., Chiang Y.L., Qian J., Bardwaj L., and Bohn M.C. Behavioural and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp Neurol 154 (1998) 261-275
16. Cools A.R., Prinssen E.P.M., Ellenbroek B.A., and Heeren D.J. Role of olfactory tubercle and nucleus accumbens in the effects of classical and atypical neuroleptics: search for regional specificity. In: Palomo T., Archer T., and Beninger R.J. (Eds). Strategies for studying brain disorders Vol. 2 (1994), Farrand Press, London 33-53
17. Crocker S.J., Smith P.D., Jackson-Lewis V., Lamba W.R., Hayley S.P., Grimm E., Callaghan S.M., Slack R.S., Melloni E., Przedborski S., Robertson G.S., Anisman H., Merali Z., and Park D.S. Inhibition of calpains prevents neuronal and behavioural deficits in an MPTP mouse model of Parkinson's disease. J Neurosci 23 (2003) 4081-4091
18. Crocker S.J., Wigle N., Liston P., Thompson C.S., Lee C.J., Xu D., Roy S., Nicholson D.W., Park D.S., MacKenzie A., Korneluk R.G., and Robertson G.S. NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6- OHDA rat model of Parkinson's disease. Eur J Neurosci 14 (2001) 391-400
19. Curtius H.C., Wolfensberger M., Steinmann B., Redweik U., and Siegfried J. Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. J Chromatogr 99 (1974) 529-540
20. Domesick V.B. Neuroanatomical organization of dopamine neurons in the ventral tegmental area. Ann N Y Acad Sci 537 (1988) 10-26
21. Doucet J.P., Nakabeppu Y., Bedard P.J., Hope B.T., Nestler E.J., Jasmin B.J., Chen J.S., Iadarola M.J., St Jean M., Wigle N., Blanchet P., Grondin R., and Robertson G.S. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of DeltaFosB-like protein (s) in both the rodent and primate striatum. Eur J Neurosci 8 (1996) 365-381
22. Dunnett S.B., and Iversen S.D. Sensorimotor impairments following localized kainic acid and 6-hydroxydopamine lesions of the neostriatum. Brain Res 248 (1982) 121-127
23. Ebert A.D., Chen F., He X., Cryns V.L., and Bohn M.C. A tetracycline-regulated adenovirus encoding dominant-negative caspase-9 is regulated in rat brain and protects against neurotoxin-induced cell death in vitro, but not in vivo. Exp Neurol 191 Suppl 1 (2005) S80-S94
24. Ebert A.D., Hann H.J., and Bohn M.C. Progressive degeneration of dopamine neurons in 6-hydroxydopamine rat model of Parkinson's disease does not involve activation of caspase-9 and caspase-3. J Neurosci Res 86 (2008) 317-325
25. Elkon H., Melamed E., and Offen D. 6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. Cell Mol Neurobiol 21 (2001) 771-781
26. Ellenbroek B.A., Van den H.J., and Cools A.R. The nucleus accumbens and forelimb muscular rigidity in rats. Exp Brain Res 72 (1988) 299-304
27. Fallon J.H. Collateralization of monoamine neurons: mesotelencephalic dopamine projections to caudate, septum, and frontal cortex. J Neurosci 1 (1981) 1361-1368
28. Fleming S.M., Delville Y., and Schallert T. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. Behav Brain Res 156 (2005) 201-213
29. 2+ release from mitochondria. FEBS Lett 198 (1986) 99-102
30. Gafni J., and Ellerby L.M. Calpain activation in Huntington's disease. J Neurosci 22 (2002) 4842-4849
31. Gerlach M., Riederer P., Przuntek H., and Youdim M.B. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol 208 (1991) 273-286
32. Grant R.J., and Clarke P.B. Susceptibility of ascending dopamine projections to 6-hydroxydopamine in rats: effect of hypothermia. Neuroscience 115 (2002) 1281-1294
33. Hall E.D., Sullivan P.G., Gibson T.R., Pavel K.M., Thompson B.M., and Scheff S.W. Spatial and temporal characteristics of neurodegeneration after controlled cortical impact in mice: more than a focal brain injury. J Neurotrauma 22 (2005) 252-265
34. Hanrott K., Murray T.K., Orfali Z., Ward M., Finlay C., O'Neill M.J., and Wonnacott S. Differential activation of PKCdelta in the substantia nigra of rats following striatal or nigral 6-hydroxydopamine lesions. Eur J Neurosci 27 (2008) 1086-1096
35. Hartmann A., Hunot S., Michel P.P., Muriel M.P., Vyas S., Faucheux B.A., Mouatt-Prigent A., Turmel H., Srinivasan A., Ruberg M., Evan G.I., Agid Y., and Hirsch E.C. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A 97 (2000) 2875-2880
36. Hartmann A., Troadec J.D., Hunot S., Kikly K., Faucheux B.A., Mouatt-Prigent A., Ruberg M., Agid Y., and Hirsch E.C. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci 21 (2001) 2247-2255
37. Higuchi M., Tomioka M., Takano J., Shirotani K., Iwata N., Masumoto H., Maki M., Itohara S., and Saido T.C. Distinct mechanistic roles of calpain and caspase activation in neurodegeneration as revealed in mice overexpressing their specific inhibitors. J Biol Chem 280 (2005) 15229-15237
38. Hoglinger G.U., Carrard G., Michel P.P., Medja F., Lombes A., Ruberg M., Friguet B., and Hirsch E.C. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J Neurochem 86 (2003) 1297-1307
39. Jayanthi S., Deng X., Noailles P.A., Ladenheim B., and Cadet J.L. Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades. FASEB J 18 (2004) 238-251
40. Jellinger K., Linert L., Kienzl E., Herlinger E., and Youdim M.B. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J Neural Transm Suppl 46 (1995) 297-314
41. Joyce J.N. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system. Exp Neurol 113 (1991) 261-276
42. Joyce J.N. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. II. Effects of 6-hydroxydopamine or colchicine microinjections into the VTA or reserpine treatment. Exp Neurol 113 (1991) 277-290
43. 2+ on binding of the calpains to calpastatin. J Biol Chem 264 (1989) 17888-17896
44. Kirik D., Winkler C., and Bjorklund A. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J Neurosci 21 (2001) 2889-2896
45. Kuo H., Ingram D.K., Crystal R.G., and Mastrangeli A. Retrograde transfer of replication deficient recombinant adenovirus vector in the central nervous system for tracing studies. Brain Res 705 (1995) 31-38
46. Lankiewicz S., Marc L.C., Truc B.N., Krohn A.J., Poppe M., Cole G.M., Saido T.C., and Prehn J.H. Activation of calpain I converts excitotoxic neuron death into a caspase-independent cell death. J Biol Chem 275 (2000) 17064-17071
47. Lee M.S., and Tsai L.H. Cdk5: one of the links between senile plaques and neurofibrillary tangles?. J Alzheimers Dis 5 (2003) 127-137
48. Liang C.L., Sinton C.M., Sonsalla P.K., and German D.C. Midbrain dopaminergic neurons in the mouse that contain calbindin-D28k exhibit reduced vulnerability to MPTP-induced neurodegeneration. Neurodegeneration 5 (1996) 313-318
49. Loughlin S.E., and Fallon J.H. Mesostriatal projections from ventral tegmentum and dorsal raphe: cells project ipsilaterally or contralaterally but not bilaterally. Neurosci Lett 32 (1982) 11-16
50. Louis M., and Clarke P.B.S. Effect of ventral tegmental 6-hydroxydopamine lesions on the locomotor stimulant action of nicotine in rats. Neuropharmacology 37 (1998) 1503-1513
51. Mandel R.J., Spratt S.K., Snyder R.O., and Leff S.E. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci U S A 94 (1997) 14083-14088
52. McCollum A.T., Nasr P., and Estus S. Calpain activates caspase-3 during UV-induced neuronal death but only calpain is necessary for death. J Neurochem 82 (2002) 1208-1220
53. Melloni E., De Tullio R., Averna M., Tedesco I., Salamino F., Sparatore B., and Pontremoli S. Properties of calpastatin forms in rat brain. FEBS Lett 431 (1998) 55-58
54. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., and Nagatsu T. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. J Neural Transm 107 (2000) 335-341
55. Mouatt-Prigent A., Agid Y., and Hirsch E.C. Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?. Brain Res 668 (1994) 62-70
56. Mouatt-Prigent A., Karlsson J.O., Agid Y., and Hirsch E.C. Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death?. Neuroscience 73 (1996) 979-987
57. Neumar R.W., Xu Y.A., Gada H., Guttmann R.P., and Siman R. Cross-talk between calpain and caspase proteolytic systems during neuronal apoptosis. J Biol Chem 278 (2003) 14162-14167
58. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., Lanciego J.L., Artieda J., Gonzalo N., and Olanow C.W. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23 (2000) S8-S19
59. O'Dell S.J., Gross N.B., Fricks A.N., Casiano B.D., Nguyen T.B., and Marshall J.F. Running wheel exercise enhances recovery from nigrostriatal dopamine injury without inducing neuroprotection. Neuroscience 144 (2007) 1141-1151
60. Olsson M., Nikkhah G., Bentlage C., and Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15 (1995) 3863-3875
61. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1997), Academic Press, San Diego, CA
62. Pike B.R., Zhao X., Newcomb J.K., Posmantur R.M., Wang K.K., and Hayes R.L. Regional calpain and caspase-3 proteolysis of alpha-spectrin after traumatic brain injury. Neuroreport 9 (1998) 2437-2442
63. Pisa M. Motor functions of the striatum in the rat: critical role of the lateral region in tongue and forelimb reaching. Neuroscience 24 (1988) 453-463
64. Prasher D.C., Eckenrode V.K., Ward W.W., Prendergast F.G., and Cormier M.J. Primary structure of the Aequorea victoria green-fluorescent protein. Gene 111 (1992) 229-233
65. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., and Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67 (1995) 631-647
66. Rami A., Agarwal R., Botez G., and Winckler J. mu-Calpain activation, DNA fragmentation, and synergistic effects of caspase and calpain inhibitors in protecting hippocampal neurons from ischemic damage. Brain Res 866 (2000) 299-312
67. Ranaldi R., and Wise R.A. Blockade of D1 dopamine receptors in the ventral tegmental area decreases cocaine reward: possible role for dendritically released dopamine. J Neurosci 21 (2001) 5841-5846
68. Ray S.K., and Banik N.L. Calpain and its involvement in the pathophysiology of CNS injuries and diseases: therapeutic potential of calpain inhibitors for prevention of neurodegeneration. Curr Drug Target CNS Neurol Disord 2 (2003) 173-189
69. Ray S.K., Matzelle D.D., Wilford G.G., Hogan E.L., and Banik N.L. Inhibition of calpain-mediated apoptosis by E-64 d-reduced immediate early gene (IEG) expression and reactive astrogliosis in the lesion and penumbra following spinal cord injury in rats. Brain Res 916 (2001) 115-126
70. Reimertz C., Kogel D., Lankiewicz S., Poppe M., and Prehn J.H. Ca(2+)-induced inhibition of apoptosis in human SH-SY5Y neuroblastoma cells: degradation of apoptotic protease activating factor-1 (APAF-1). J Neurochem 78 (2001) 1256-1266
71. Roberts-Lewis J.M., Savage M.J., Marcy V.R., Pinsker L.R., and Siman R. Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain. J Neurosci 14 (1994) 3934-3944
72. Saatman K.E., Bozyczko-Coyne D., Marcy V., Siman R., and McIntosh T.K. Prolonged calpain-mediated spectrin breakdown occurs regionally following experimental brain injury in the rat. J Neuropathol Exp Neurol 55 (1996) 850-860
73. Saido T.C., Yokota M., Nagao S., Yamaura I., Tani E., Tsuchiya T., Suzuki K., and Kawashima S. Spatial resolution of fodrin proteolysis in postischemic brain. J Biol Chem 268 (1993) 25239-25243
74. Sauer H., and Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59 (1994) 401-415
75. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., and Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39 (2000) 777-787
76. Schallert T., and Tillerson J.L. Intervention strategies for degeneration of dopamine neurons in Parkinsonism: optimizing behavioural assessment of outcome. In: Emerich D.F., Dean R.L., and Sanberg P.R. (Eds). Central nervous system disease: innovative animal models from lab to clinic (2000), Humana Press, Totawa, NJ 131-151
77. Schapira A.H., and Olanow C.W. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291 (2004) 358-364
78. Schumacher P.A., Siman R.G., and Fehlings M.G. Pretreatment with calpain inhibitor CEP-4143 inhibits calpain I activation and cytoskeletal degradation, improves neurological function, and enhances axonal survival after traumatic spinal cord injury. J Neurochem 74 (2000) 1646-1655
79. Smith P.D., Mount M.P., Shree R., Callaghan S., Slack R.S., Anisman H., Vincent I., Wang X., Mao Z., and Park D.S. Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J Neurosci 26 (2006) 440-447
80. Staszewski R.D., and Yamamoto B.K. Methamphetamine-induced spectrin proteolysis in the rat striatum. J Neurochem 96 (2006) 1267-1276
81. Storch A., Kaftan A., Burkhardt K., and Schwarz J. 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism. J Neural Transm 107 (2000) 281-293
82. Tan Y., Williams E.A., Lancia A.J., and Zahm D.S. On the altered expression of tyrosine hydroxylase and calbindin-D 28kD immunoreactivities and viability of neurons in the ventral tegmental area of Tsai following injections of 6-hydroxydopamine in the medial forebrain bundle in the rat. Brain Res 869 (2000) 56-68
83. Tan Y., Williams E.S., and Zahm D.S. Calbindin-D 28kD immunofluorescence in ventral mesencephalic neurons labeled following injections of Fluoro-Gold in nucleus accumbens subterritories: inverse relationship relative to known neurotoxin vulnerabilities. Brain Res 844 (1999) 67-77
84. Tawa P., Hell K., Giroux A., Grimm E., Han Y., Nicholson D.W., and Xanthoudakis S. Catalytic activity of caspase-3 is required for its degradation: stabilization of the active complex by synthetic inhibitors. Cell Death Differ 11 (2004) 447
85. Thomas J., Wang J., Takubo H., Sheng J., de Jesus S., and Bankiewicz K.S. A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioural characterization. Exp Neurol 126 (1994) 159-167
86. Vanderklish P.W., and Bahr B.A. The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. Int J Exp Pathol 81 (2000) 323-339
87. Wang K.K. Calpain and caspase: can you tell the difference?. Trends Neurosci 23 (2000) 59
88. Wingrave J.M., Schaecher K.E., Sribnick E.A., Wilford G.G., Ray S.K., Hazen-Martin D.J., Hogan E.L., and Banik N.L. Early induction of secondary injury factors causing activation of calpain and mitochondria-mediated neuronal apoptosis following spinal cord injury in rats. J Neurosci Res 73 (2003) 95-104
89. Winkler C., Kirik D., Bjorklund A., and Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10 (2002) 165-186
90. Winkler C., Sauer H., Lee C.S., and Bjorklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 16 (1996) 7206-7215
91. Wu H.Y., Tomizawa K., Oda Y., Wei F.Y., Lu Y.F., Matsushita M., Li S.T., Moriwaki A., and Matsui H. Critical role of calpain-mediated cleavage of calcineurin in excitotoxic neurodegeneration. J Biol Chem 279 (2004) 4929-4940
92. Yokota M., Saido T.C., Tani E., Kawashima S., and Suzuki K. Three distinct phases of fodrin proteolysis induced in postischemic hippocampus. Involvement of calpain and unidentified protease. Stroke 26 (1995) 1901-1907
93. Zigmond M.J., Acheson A.L., Stachowiak M.K., and Stricker E.M. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch Neurol 41 (1984) 856-861